GoodRx Releases Fourth Quarter and Full Year 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- S&P 500 ends near flat as investors focus on US-Iran war
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Plug Power COO resigns to join another company
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- Wall Street ends down as oil prices, Treasury yields rise
GoodRx Holdings Inc. (GDRX) PT Lowered to $30 at Goldman Sachs
March 1, 2022 6:58 AM ESTGoldman Sachs analyst Eric Sheridan lowered the price target on GoodRx Holdings Inc. (NASDAQ: GDRX) to $30.00 (from $43.00) while maintaining a Buy rating following results.
The analyst commented, "We reiterate our Buy rating but lower our PT from $43 to $30 to reflect both lowered operating... More
GoodRx Holdings Inc. (GDRX) PT Lowered to $20 at JPMorgan
March 1, 2022 4:58 AM ESTJPMorgan analyst Doug Anmuth lowered the price target on GoodRx Holdings Inc. (NASDAQ: GDRX) to $20.00 (from $33.00) while maintaining a Underweight rating.
The analyst comments "GoodRx is focused on building the top consumer-focused digital healthcare platform in the US. Its core offering tracks... More
GoodRx (GDRX) Shares Down 28% on Q4 Miss, Weak Outlook
February 28, 2022 5:31 PM ESTGoodRx Holdings, Inc. (NASDAQ: GDRX) shares were trading around 28% lower after-hours following the companys disappointing Q4 results. Quarterly EPS came in at $0.09, missing the consensus estimate of $0.10.
Revenue was $213.3 million, compared to the consensus estimate of $217.53 million. Prescription Transactions revenue increased 21% year-over-year... More
GoodRx Holdings, Inc. (GDRX) Misses Q4 EPS by 1c; Guides Q1 Revs Below the Street
February 28, 2022 4:13 PM ESTGoodRx Holdings, Inc. (NASDAQ: GDRX) reported Q4 EPS of $0.09, $0.01 worse than the analyst estimate of $0.10. Revenue for the quarter came in at $213.3 million versus the consensus estimate of $217.53 million.
GUIDANCE:
GoodRx Holdings, Inc. sees Q1 2022 revenue of ~$200 million, versus the... More
